DDInter1822 DDInter1763
Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cystic fibrosis patients, as _P. aeruginosa_ is notoriously inherently resistant to many antibiotics.[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.[A232294, A232349, L
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Tobramycin {u} (Compound) causes {v} (Side Effect) Pharyngitis
Pharyngitis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Tobramycin {u} (Compound) causes {v} (Side Effect) Pharyngitis
Pharyngitis {u} (Side Effect) is caused by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Tobramycin {u} (Compound) resembles {v} (Compound) Paromomycin
Paromomycin {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Tobramycin {u} (Compound) resembles {v} (Compound) Kanamycin
Kanamycin {u} (Compound) upregulates {v} (Gene) SSBP2
SSBP2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Tobramycin {u} (Compound) resembles {v} (Compound) Kanamycin
Kanamycin {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Tobramycin {u} (Compound) resembles {v} (Compound) Paromomycin
Paromomycin {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Tobramycin {u} (Compound) resembles {v} (Compound) Gentamicin
Gentamicin {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Tobramycin {u} (Compound) resembles {v} (Compound) Kanamycin
Kanamycin {u} (Compound) downregulates {v} (Gene) CDKN1B
CDKN1B {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Tobramycin (Compound) causes Pharyngitis (Side Effect) and Pharyngitis (Side Effect) is caused by Temsirolimus (Compound)
Tobramycin (Compound) causes Pharyngitis (Side Effect) and Pharyngitis (Side Effect) is caused by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Tobramycin (Compound) resembles Paromomycin (Compound) and Paromomycin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Temsirolimus (Compound)
Tobramycin (Compound) resembles Kanamycin (Compound) and Kanamycin (Compound) upregulates SSBP2 (Gene) and SSBP2 (Gene) is upregulated by Temsirolimus (Compound)
Tobramycin (Compound) resembles Kanamycin (Compound) and Kanamycin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Tobramycin (Compound) resembles Paromomycin (Compound) and Paromomycin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Temsirolimus (Compound)
Tobramycin (Compound) resembles Gentamicin (Compound) and Gentamicin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Tobramycin (Compound) resembles Kanamycin (Compound) and Kanamycin (Compound) downregulates CDKN1B (Gene) and CDKN1B (Gene) is upregulated by Temsirolimus (Compound)